Celgene Reports Data From Phase III Study Of REVLIMID

(RTTNews) - Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (CELG), Thursday announced that data from FIRST, its phase III study of REVLIMID, in combination with dexamethasone in patients newly diagnosed with multiple myeloma ineligible for stem cell transplant will be presented on Dcember 8. The primary endpoint was a comparison of progression-free survival in Arm A vs. Arm C. Secondary endpoints included overall survival, overall response rate,time to response, duration of response, safety and quality of life.

FIRST stands for Frontline Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide. REVLIMID is not indicated for newly-diagnosed multiple myeloma in any country.